Immunogenicity of drug delivery vehicles causes treatment failures in significant patient populations

Pharmaceutical researchers and biotech companies struggle with immunogenic responses to drug delivery vehicles (nanoparticles, viral vectors, liposomes) that render treatments ineffective for a substantial portion of patients. Current solutions fail to reliably predict or prevent immune rejection before clinical trials, forcing expensive late-stage failures and limiting addressable patient populations for otherwise promising therapies.